Drug Profile
Research programme: bispecific antibodies - BioNTech/Genmab
Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator BioNTech; Genmab
- Class Bispecific antibodies; Cancer vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 06 May 2019 Preclinical trials in Cancer in Denmark (Parenteral)